Tesamorelin is unique among peptides in men's health: it is the only FDA-approved peptide specifically indicated for visceral fat reduction. Originally approved for HIV-associated lipodystrophy, Tesamorelin has become one of the most sought-after compounds for men seeking to address the visceral adiposity that accumulates with age, metabolic syndrome, and declining GH levels.
Visceral Fat: The Most Dangerous Fat
Visceral fat — the fat that accumulates around the abdominal organs — is metabolically distinct from subcutaneous fat. It is highly inflammatory, secreting adipokines that drive insulin resistance, cardiovascular disease, and systemic inflammation. For men, visceral fat accumulation is the primary driver of the "metabolic syndrome" pattern that becomes increasingly common after age 40.
The Tesamorelin Mechanism
Tesamorelin is a GHRH analog that stimulates the pituitary to release GH. GH, in turn, activates hormone-sensitive lipase in adipocytes — particularly visceral adipocytes, which express higher levels of GH receptors than subcutaneous fat cells. This creates a preferential lipolytic effect on visceral fat, with clinical trials demonstrating 15-20% reductions in visceral adipose tissue with 6-12 months of treatment.
IGF-1 and Anabolic Effects
Tesamorelin also elevates IGF-1 levels significantly, which has anabolic effects on lean mass. For men seeking simultaneous visceral fat reduction and lean mass preservation, Tesamorelin offers a dual mechanism that makes it particularly valuable in the context of body recomposition.